Mirati reports Phase II data for mocetinostat, Imfinzi combo

Mirati Therapeutics Inc. (NASDAQ:MRTX) reported data from 23 evaluable non-small cell lung cancer (NSCLC) patients

Read the full 151 word article

User Sign In